NASDAQ:VVUSVIVUS Stock Price, Forecast & News

VIVUS's stock was trading at $1.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VVUS stock has decreased by 41.9% and is now trading at $0.6046. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VIVUS in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for VIVUS.

VIVUS is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for VIVUS.

VIVUS, Inc. (NASDAQ:VVUS) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter. View VIVUS's earnings history.

VIVUS shares reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

1 brokerages have issued 1-year target prices for VIVUS's shares. Their forecasts range from $1.75 to $1.75. On average, they expect VIVUS's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 189.4% from the stock's current price. View analysts' price targets for VIVUS.

Media coverage about VVUS stock has trended somewhat negative recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. VIVUS earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about VIVUS.

Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Novavax (NVAX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Melinta Therapeutics (MLNT), Inovio Pharmaceuticals (INO), General Electric (GE), Pfizer (PFE) and Arena Pharmaceuticals (ARNA).

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VVUS stock can currently be purchased for approximately $0.60.

VIVUS has a market capitalization of $10.80 million and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. VIVUS employs 57 workers across the globe.

The official website for VIVUS is www.vivus.com.

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]